Levin Capital Strategies L.P. Has $559,000 Stake in Alpha Tau Medical Ltd. (NASDAQ:DRTS)

Key Points

• Levin Capital Strategies L.P. reduced its holdings in Alpha Tau Medical by 29.3%, selling 92,000 shares and bringing its ownership to approximately $559,000.
• HC Wainwright has maintained a "buy" rating for Alpha Tau Medical, setting a target price of $9.00 per share.
• Alpha Tau Medical reported an earnings per share of ($0.12) for the recent quarter, surpassing analyst expectations of ($0.14).

Levin Capital Strategies L.P. decreased its position in Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) by 29.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 222,514 shares of the company's stock after selling 92,000 shares during the period. Levin Capital Strategies L.P. owned about 0.32% of Alpha Tau Medical worth $559,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of DRTS. XTX Topco Ltd acquired a new stake in shares of Alpha Tau Medical in the first quarter valued at approximately $53,000. Renaissance Technologies LLC grew its position in Alpha Tau Medical by 188.7% in the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after purchasing an additional 26,800 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock valued at $151,000 after buying an additional 25,770 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company's stock.

Alpha Tau Medical Stock Up 3.7%

DRTS stock traded up $0.12 during mid-day trading on Friday, reaching $3.39. The company had a trading volume of 96,722 shares, compared to its average volume of 63,385. The company has a market capitalization of $287.54 million, a price-to-earnings ratio of -7.37 and a beta of 0.99. Alpha Tau Medical Ltd. has a 52 week low of $2.06 and a 52 week high of $4.39. The stock has a 50 day simple moving average of $3.05 and a two-hundred day simple moving average of $2.95. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.81 and a quick ratio of 5.81.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings data on Monday, May 19th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. As a group, equities analysts predict that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, April 29th.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.